Albany, NY -- (SBWIRE) -- 07/27/2017 -- Hospital infectious disease testing is a procedure to identify hospital acquired/related infections. Hospital infections are among the most prominent challenges faced by health care delivery systems across the globe. Hospital infectious diseases are considered a significant cause of death globally. These are acquired while receiving health care treatment. Hospital infectious diseases tests are performed by health care professionals, especially clinical laboratory technicians, for the diagnosis of infections.
Obtain the Comprehensive Overview of Hospital Infectious Disease Testing Market: http://www.transparencymarketresearch.com/hospital-infectious-disease-testing-market.html
Based on test type, the global hospital infectious disease testing market has been broadly segmented into:
> Urinary tract infection (UTI)
> Surgical site Infection
> Bloodstream infection
The UTI segment accounted for the major share of the hospital infectious disease testing market, followed by surgical site infections and pneumonia. Hospital infectious diseases are required to be closely monitored due to increase in antimicrobial resistance in some regions. Automated urine microscopy is the most preferred diagnostic tool adopted by clinical technicians for UTI. Prevalence of pneumonia and deaths associated with it are increasing gradually. Other hospital infections include cardiovascular, systemic, joint and bone, respiratory, and ENT (enteric) infections.
The hospital infectious disease testing market has experienced strong growth in the last decade due to factors such as increased awareness about growth in the incidence of infections globally and development of innovative prevention and treatment solutions. Major factors driving the market are establishment of quality government guidelines and uniform code for prevention of hospital infectious diseases. Lack of funding and skilled manpower in developing countries and lack of stringent guidelines and framework to control the morbidity rate of hospital infections are restraining the hospital infectious disease testing market. Lack of controlling authorities and controlling programs in lesser developed regions is another major factor hampering market growth. Technological development of molecular diagnostics and passage of the Patient Care and Affordable Care Act in the U.S. are likely to offer significant opportunities in the market in the near future.
Geographically, the global hospital infectious disease testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the market due to growing patient awareness, favorable initiatives taken by the federal government, and large number of market players based in the region. The hospital infectious disease testing market in Europe is mature due to presence of strong and active hospital infection control and prevention authorities and guidelines such as the NHS in the U.K. Moreover, Europe is considered the hub for the global geriatric population. It is observed that geriatrics are more prone to various infections. This is likely to increase demand in Europe. Asia Pacific is a lucrative market for hospital infectious disease testing products as the overall prevalence of the infections in this region is high. Moreover, stringent guidelines have been set for the prevention and control of such conditions in the health care infrastructure in this region. Countries such as China, India, Japan, Thailand, Australia, and the Philippines are expected to be the major contributors to the hospital infectious disease testing market in Asia Pacific. Latin America and Middle East & Africa are considered the emerging markets for hospital infectious disease testing. This is attributed to increasing investment by governments for effective health care infrastructure in the region.
Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20612
Key players operating in the hospital infectious disease testing market include Abbott Laboratories, Alere, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation), Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., Siemens Healthineers, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Cepheid, Inc., and QIAGEN.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.